Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
Invex Therapeutics Ltd. (IXC) Share Price & Analysis
3 Followers
IXC Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.04 - AU$0.16
Previous CloseAU$0.09
Volume782.00
Average Volume (3M)69.15K
Market Cap
AU$6.39M
Enterprise Value-AU$22.95M
Total Cash (Recent Filing)AU$29.34M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)-1.1
Beta-0.09
Next Earnings
Aug 15, 2024EPS EstimateN/A
Last Dividend Ex-Date
Dec 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding75,153,848
10 Day Avg. Volume132,756
30 Day Avg. Volume69,147
Standard Deviation0.25
R-Squared0.30
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Invex Therapeutics Ltd. News
PremiumCompany Announcements
Invex Therapeutics Advances Exenatide Development
PremiumCompany Announcements
Invex Therapeutics Director Adjusts HoldingsOptions Prices
Currently, No data available
---
Ownership Overview
4.87% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
95.13% Public Companies and
Individual Investors
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.04 and its highest was AU$0.16 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Aug 15, 2024 which is in 118 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Invex Therapeutics Ltd. released its earnings results on Feb 15, 2024. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.19 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Invex Therapeutics Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
---
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.64%
12-Months-Change
Fundamentals
Return on Equity
-40.06%
Trailing 12-Months
Asset Growth
-75.75%
Trailing 12-Months
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.
---
Technical Analysis
---